Abstract:Background: The optimal duration of dual antiplatelet therapy after currently available drug-eluting stent (DES) implantation to prevent stent thrombosis (ST) remains controversial. Delayed healing is frequently identified as a leading cause of ST in the early phase. However, a thorough pathological investigation into strut coverage after currently available DES implantation is lacking-a gap addressed in the current study. Methods: From our autopsy registry of 199 stented lesions, 4,713 struts from 66 currently available DES-stented lesions with an implant duration ≤370 days were histologically evaluated. Endothelial coverage was defined as the presence of luminal endothelial cells overlying struts and an underlying smooth muscle cell layer. The stented lesions were classified into acute coronary syndrome (ACS) (n = 40) and chronic coronary syndrome (CCS) (n = 26) groups and were compared. Endothelial coverage predictors were identified through logistic analysis. Results: Although ACS and CCS lesions presented comparable clinical characteristics, including age, sex, and cause of death, the latter exhibited a significantly higher prevalence of chronic kidney disease and hemodialysis than the former (33.3% vs. 65.2%; P = .02, 7.7% vs. 30.4%; P = .02). The poststent implant median duration was significantly shorter in ACS lesions than in CCS lesions (13 [IQR 5-26 days] vs. 40 [IQR 16-233 days]; P < .01). The endothelial coverage percentage was 3.5% at 30 days and 27.7% at 90 days after currently available DES implantation. Multivariable logistic regression analysis implicated implant duration of ≤90 days (odds ratio [OR], 0.009; 95% confidence interval [CI], 0.006-0.012; P < .01), superficial calcification (OR, 0.11; 95% CI, 0.07-0.17; P < .01), ACS culprit site (OR, 0.29; 95% CI, 0.09-0.94; P = .039), and circumferentially durable polymer-coated DES (OR, 0.32; 95% CI, 0.24-0.41; P < .01) as delayed endothelial coverage predictors. Conclusions: Endothelial coverage was limited at 90 days after currently available DES implantation, and the ACS culprit site and circumferentially durable polymer-coated DES were identified as independent predictors of delayed endothelial coverage. Our findings suggest the importance of underlying plaque morphology and stent technology for vessel healing after such implantation.

Very long-term serial luminal changes after sirolimus-eluting stent implantation and progression process of very late stent failure

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Comparison of the “late Catch-Up” Phenomenon Between BuMA Supreme and XIENCE Stents Through Serial Optical Coherence Tomography at 1–2 Month and 2 Year Follow-Ups: A Multicenter Study

Quantitative Assessment of Late Lumen Loss after Biodegradable Polymer and Permanent Polymer Sirolimus-Eluting Stents Implantation

Fifteen-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation

Impact of optical coherence tomography-derived neointimal tissue morphology on development of very late in-stent restenosis

Clinical Outcomes of Deferred Lesions with Angiographically Insignificant Stenosis but Low Fractional Flow Reserve.

Angiographic analysis of pattern of late luminal loss in sirolimus- and paclitaxel-eluting stents.

Endovascular Nitinol Stenting for Long Occlusive Disease of the Superficial Femoral Artery in Critical Limb Ischemia: A Single-Center, Mid-Term Result

Clinical and Angiographic Outcome after Sirolimus-Eluting Stent Implantation in Aorto-Ostial Lesions.

Immediate and Mid-Term Outcomes of Sirolimus-Eluting Stent Implantation for Chronic Total Occlusions

Comparison of Long-Term In-Stent Vascular Response Between Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent and Durable Polymer Everolimus-Eluting Stent: 3-Year OCT Follow-Up from the TARGET I Trial

[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]

Long‐term Clinical, Angiographic, and Intravascular Ultrasound Outcomes of Biodegradable Polymer‐coated Sirolimus‐eluting Stents

Pathological evaluation of predictors for delayed endothelial coverage after currently available drug-eluting stent implantation in coronary arteries: Impact of lesions with acute and chronic coronary syndromes

Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the TARGET II Trial.

TCT-567 Long-Term Outcomes with an Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent Versus a Cobalt-Chromium Everolimus-Eluting Stent in Single De Novo Coronary Lesions: Four-Year Results of the TARGET I Randomized Controlled Trial

Long-term Outcomes Following Drug-Eluting Stent Implantation in Unprotected Left Main Bifurcation Lesions.

Long-term serial changes in platelet activation indices following sirolimus elution and bare metal stent implantation in patients with stable coronary artery disease

Randomized Clinical Trial Comparing Abluminal Biodegradable Polymer Sirolimus-Eluting Stents With Durable Polymer Sirolimus-Eluting Stents: Nine Months Angiographic And 5-Year Clinical Outcomes

Very Late Stent Thrombosis in Late Stent Malapposition After Sirolimus-Eluting Stent Implantation